179 related articles for article (PubMed ID: 9499111)
21. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
[TBL] [Abstract][Full Text] [Related]
22. Peptide ligands selected with CD4-induced epitopes on native dualtropic HIV-1 envelope proteins mimic extracellular coreceptor domains and bind to HIV-1 gp120 independently of coreceptor usage.
Dervillez X; Klaukien V; Dürr R; Koch J; Kreutz A; Haarmann T; Stoll M; Lee D; Carlomagno T; Schnierle B; Möbius K; Königs C; Griesinger C; Dietrich U
J Virol; 2010 Oct; 84(19):10131-8. PubMed ID: 20660187
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals.
Beddows S; Lister S; Cheingsong R; Bruck C; Weber J
J Virol; 1999 Feb; 73(2):1740-5. PubMed ID: 9882391
[TBL] [Abstract][Full Text] [Related]
24. Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity.
Foda M; Harada S; Maeda Y
Microbiol Immunol; 2001; 45(7):521-30. PubMed ID: 11529558
[TBL] [Abstract][Full Text] [Related]
25. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1.
Schønning K; Jansson B; Olofsson S; Hansen JE
J Gen Virol; 1996 Apr; 77 ( Pt 4)():753-8. PubMed ID: 8627264
[TBL] [Abstract][Full Text] [Related]
26. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
Derdeyn CA; Decker JM; Sfakianos JN; Wu X; O'Brien WA; Ratner L; Kappes JC; Shaw GM; Hunter E
J Virol; 2000 Sep; 74(18):8358-67. PubMed ID: 10954535
[TBL] [Abstract][Full Text] [Related]
27. Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization.
Zhang YJ; Fredriksson R; McKeating JA; Fenyö EM
Virology; 1997 Nov; 238(2):254-64. PubMed ID: 9400598
[TBL] [Abstract][Full Text] [Related]
28. Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies.
Nabatov AA; Pollakis G; Linnemann T; Kliphius A; Chalaby MI; Paxton WA
J Virol; 2004 Jan; 78(1):524-30. PubMed ID: 14671134
[TBL] [Abstract][Full Text] [Related]
29. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4.
Cho MW; Lee MK; Carney MC; Berson JF; Doms RW; Martin MA
J Virol; 1998 Mar; 72(3):2509-15. PubMed ID: 9499115
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
[TBL] [Abstract][Full Text] [Related]
31. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1.
Armstrong SJ; McInerney TL; McLain L; Wahren B; Hinkula J; Levi M; Dimmock NJ
J Gen Virol; 1996 Dec; 77 ( Pt 12)():2931-41. PubMed ID: 9000083
[TBL] [Abstract][Full Text] [Related]
32. Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity.
LaBranche CC; Hoffman TL; Romano J; Haggarty BS; Edwards TG; Matthews TJ; Doms RW; Hoxie JA
J Virol; 1999 Dec; 73(12):10310-9. PubMed ID: 10559349
[TBL] [Abstract][Full Text] [Related]
33. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
Ly A; Stamatatos L
J Virol; 2000 Aug; 74(15):6769-76. PubMed ID: 10888615
[TBL] [Abstract][Full Text] [Related]
34. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.
Jensen MA; Li FS; van 't Wout AB; Nickle DC; Shriner D; He HX; McLaughlin S; Shankarappa R; Margolick JB; Mullins JI
J Virol; 2003 Dec; 77(24):13376-88. PubMed ID: 14645592
[TBL] [Abstract][Full Text] [Related]
35. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
Gorny MK; Williams C; Volsky B; Revesz K; Cohen S; Polonis VR; Honnen WJ; Kayman SC; Krachmarov C; Pinter A; Zolla-Pazner S
J Virol; 2002 Sep; 76(18):9035-45. PubMed ID: 12186887
[TBL] [Abstract][Full Text] [Related]
36. Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.
Hogervorst E; de Jong J; van Wijk A; Bakker M; Valk M; Nara P; Goudsmit J
J Virol; 1995 Oct; 69(10):6342-51. PubMed ID: 7666535
[TBL] [Abstract][Full Text] [Related]
37. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
[TBL] [Abstract][Full Text] [Related]
38. Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching.
Pastore C; Nedellec R; Ramos A; Hartley O; Miamidian JL; Reeves JD; Mosier DE
J Virol; 2007 Aug; 81(15):8165-79. PubMed ID: 17507486
[TBL] [Abstract][Full Text] [Related]
39. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.
Trkola A; Ketas T; Kewalramani VN; Endorf F; Binley JM; Katinger H; Robinson J; Littman DR; Moore JP
J Virol; 1998 Mar; 72(3):1876-85. PubMed ID: 9499039
[TBL] [Abstract][Full Text] [Related]
40. Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction.
Guillon C; Schutten M; Boers PH; Gruters RA; Osterhaus AD
J Virol; 2002 Mar; 76(6):2827-34. PubMed ID: 11861850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
